Clinical study results published in NEJM show promising data on Antegren (natalizumab)
Cambridge, MA and Dublin, Ireland (January 2, 2003) Biogen, Inc. (NASDAQ:BGEN) and Elan Corporation, plc (NYSE:ELN) announced today that the results of a study published in the New England Journal of Medicine (NEJM) indicate ANTEGREN (natalizumab) reduced new inflammatory brain lesions and relapses in patients with relapsing forms of multiple sclerosis (MS). The use of natalizumab in the treatme...Antegren (natalizumab) clinical study results published in New England Journal of Medicine
Dublin, Ireland and Cambridge, MA, January 2, 2003 Elan Corporation, plc (NYSE: ELN) ("Elan") and Biogen, Inc. (NASDAQ: BGEN) ("Biogen") announce the publication of two clinical study reports on ANTEGREN (natalizumab) in today's issue of the New England Journal of Medicine. Natalizumab, a humanized monoclonal antibody, showed promising results on disease remission and improved quality of life...